HomeCompareGNFT vs STAG

GNFT vs STAG: Dividend Comparison 2026

GNFT yields 22.35% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GNFT wins by $65.9K in total portfolio value
10 years
GNFT
GNFT
● Live price
22.35%
Share price
$8.95
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$84.2K
Annual income
$8,592.87
Full GNFT calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.09
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.22
Full STAG calculator →

Portfolio growth — GNFT vs STAG

📍 GNFT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGNFTSTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GNFT + STAG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GNFT pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GNFT
Annual income on $10K today (after 15% tax)
$1,899.44/yr
After 10yr DRIP, annual income (after tax)
$7,303.94/yr
STAG
Annual income on $10K today (after 15% tax)
$292.45/yr
After 10yr DRIP, annual income (after tax)
$392.89/yr
At 15% tax rate, GNFT beats the other by $6,911.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GNFT + STAG for your $10,000?

GNFT: 50%STAG: 50%
100% STAG50/50100% GNFT
Portfolio after 10yr
$51.3K
Annual income
$4,527.54/yr
Blended yield
8.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on STAG right now

GNFT
Analyst Ratings
6
Buy
1
Sell
Consensus: Buy
Price Target
$13.00
+45.3% upside vs current
Range: $13.00 — $13.00
Altman Z
-0.1
Piotroski
2/9
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.7% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GNFT buys
0
STAG buys
0
No recent congressional trades found for GNFT or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGNFTSTAG
Forward yield22.35%3.44%
Annual dividend / share$2.00$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0.3%
Portfolio after 10y$84.2K$18.3K
Annual income after 10y$8,592.87$462.22
Total dividends collected$50.6K$4.0K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$13.00$45.00

Year-by-year: GNFT vs STAG ($10,000, DRIP)

YearGNFT PortfolioGNFT Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$12,935$2,234.64$10,665$345.09+$2.3KGNFT
2$16,541$2,701.33$11,364$357.70+$5.2KGNFT
3$20,928$3,228.58$12,098$370.43+$8.8KGNFT
4$26,210$3,817.51$12,869$383.28+$13.3KGNFT
5$32,513$4,468.32$13,677$396.23+$18.8KGNFT
6$39,970$5,180.24$14,524$409.27+$25.4KGNFT
7$48,719$5,951.60$15,411$422.41+$33.3KGNFT
8$58,909$6,779.83$16,339$435.61+$42.6KGNFT
9$70,694$7,661.60$17,311$448.89+$53.4KGNFT
10$84,236$8,592.87$18,327$462.22+$65.9KGNFT

GNFT vs STAG: Complete Analysis 2026

GNFTStock

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Full GNFT Calculator →

STAGREIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this GNFT vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GNFT vs SCHDGNFT vs JEPIGNFT vs OGNFT vs KOGNFT vs MAINGNFT vs PLDGNFT vs EQRGNFT vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.